Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885645 | 0.83 | GRM5 (0.48) | GBA1MAPK1ADORA2AADORA2BADORA1 | |
| SCHEMBL1644265 | 0.82 | GRM5 (0.51) | MKNK1MKNK2MAPK3MAPK8MAPK9 | |
| SCHEMBL1644264 | 0.82 | GRM5 (0.51) | MKNK1MKNK2MAPK3MAPK8MAPK9 | |
| SCHEMBL6886534 | 0.81 | KDM4E (0.56) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6886667 | 0.80 | ADORA1 (0.60) | MKNK1MKNK2MAPK8MAPK9ADORA2A | |
| SCHEMBL6884017 | 0.80 | ADORA1 (0.60) | MKNK1MKNK2MAPK8MAPK9ADORA2A | |
| SCHEMBL6887143 | 0.80 | KDM4E (0.59) | ADORA1 | |
| SCHEMBL28314223 | 0.79 | KDM4E (0.58) | MKNK1MKNK2GBA1MAPK8MAPK9 | |
| SCHEMBL28386712 | 0.78 | MAPK8 (0.50) | MKNK1MKNK2MAPK3MAPK8MAPK9 | |
| SCHEMBL13062703 | 0.77 | HDAC1 (0.56) | MKNK1MAPK8ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | MKNK1 1697/4885MKNK2 1678/4885GBA1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.